The histone chaperone ANP32B regulates chromatin incorporation of the atypical human histone variant macroH2A.


Journal

Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691

Informations de publication

Date de publication:
31 10 2023
Historique:
received: 03 02 2023
revised: 25 08 2023
accepted: 03 10 2023
medline: 6 11 2023
pubmed: 20 10 2023
entrez: 20 10 2023
Statut: ppublish

Résumé

All vertebrate genomes encode for three large histone H2A variants that have an additional metabolite-binding globular macrodomain module, macroH2A. MacroH2A variants impact heterochromatin organization and transcription regulation and establish a barrier for cellular reprogramming. However, the mechanisms of how macroH2A is incorporated into chromatin and the identity of any chaperones required for histone deposition remain elusive. Here, we develop a split-GFP-based assay for chromatin incorporation and use it to conduct a genome-wide mutagenesis screen in haploid human cells to identify proteins that regulate macroH2A dynamics. We show that the histone chaperone ANP32B is a regulator of macroH2A deposition. ANP32B associates with macroH2A in cells and in vitro binds to histones with low nanomolar affinity. In vitro nucleosome assembly assays show that ANP32B stimulates deposition of macroH2A-H2B and not of H2A-H2B onto tetrasomes. In cells, depletion of ANP32B strongly affects global macroH2A chromatin incorporation, revealing ANP32B as a macroH2A histone chaperone.

Identifiants

pubmed: 37858472
pii: S2211-1247(23)01312-8
doi: 10.1016/j.celrep.2023.113300
pii:
doi:

Substances chimiques

Histones 0
Chromatin 0
Histone Chaperones 0
Molecular Chaperones 0
Nucleosomes 0
ANP32B protein, human 0
Nuclear Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

113300

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests A.G.L. is a founder, CSO, and managing director of Eisbach Bio GmbH, a biotechnology company in oncology and virology.

Auteurs

Imke K Mandemaker (IK)

Biomedical Center (BMC), Department of Physiological Chemistry, Faculty of Medicine, LMU Munich, 82152 Planegg-Martinsried, Germany; Hubrecht Institute, Uppsalalaan 8, 3584CT Utrecht, the Netherlands. Electronic address: i.mandemaker@hubrecht.eu.

Evelyn Fessler (E)

Gene Center and Department of Biochemistry, LMU Munich, 81377 Munich, Germany.

David Corujo (D)

Applied Epigenetics Program, Myeloid Neoplasm Program, Josep Carreras Leukaemia Research Institute (IJC), Campus ICO-GTP-UAB, 08916 Badalona, Barcelona, Spain; Germans Trias I Pujol Research Institute (IGTP), 08916 Badalona, Barcelona, Spain.

Christiane Kotthoff (C)

Biomedical Center (BMC), Department of Physiological Chemistry, Faculty of Medicine, LMU Munich, 82152 Planegg-Martinsried, Germany.

Andreas Wegerer (A)

Biomedical Center (BMC), Department of Physiological Chemistry, Faculty of Medicine, LMU Munich, 82152 Planegg-Martinsried, Germany.

Clément Rouillon (C)

Hubrecht Institute, Uppsalalaan 8, 3584CT Utrecht, the Netherlands.

Marcus Buschbeck (M)

Applied Epigenetics Program, Myeloid Neoplasm Program, Josep Carreras Leukaemia Research Institute (IJC), Campus ICO-GTP-UAB, 08916 Badalona, Barcelona, Spain; Germans Trias I Pujol Research Institute (IGTP), 08916 Badalona, Barcelona, Spain.

Lucas T Jae (LT)

Gene Center and Department of Biochemistry, LMU Munich, 81377 Munich, Germany.

Francesca Mattiroli (F)

Hubrecht Institute, Uppsalalaan 8, 3584CT Utrecht, the Netherlands. Electronic address: f.mattiroli@hubrecht.eu.

Andreas G Ladurner (AG)

Biomedical Center (BMC), Department of Physiological Chemistry, Faculty of Medicine, LMU Munich, 82152 Planegg-Martinsried, Germany; Eisbach Bio GmbH, 82152 Planegg-Martinsried, Germany. Electronic address: andreas.ladurner@bmc.med.lmu.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH